SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
today released updated 18-month follow-up clinical
data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for
patients with advanced, relapsed or refractory, aggressive non-Hodgkin's
lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel
that was blinded to patient assignment.
